Critical Contrast: Corbus Pharmaceuticals (NASDAQ:CRBP) & Enlivex Therapeutics (NASDAQ:ENLV)

Corbus Pharmaceuticals (NASDAQ:CRBP) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Corbus Pharmaceuticals and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-57.13%	-50.91%
Enlivex Therapeutics	N/A	-62.91%	-53.33%

Valuation & Earnings

This table compares Corbus Pharmaceuticals and Enlivex Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$40.21 million	($5.51)	-1.50
Enlivex Therapeutics	N/A	N/A	-$15.01 million	($0.55)	-1.84

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Corbus Pharmaceuticals and Enlivex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	8	1	2.73
Enlivex Therapeutics	1	2	1	0	2.00

Corbus Pharmaceuticals presently has a consensus price target of $44.38, indicating a potential upside of 436.58%. Enlivex Therapeutics has a consensus price target of $13.00, indicating a potential upside of 1,187.13%. Given Enlivex Therapeutics’ higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Corbus Pharmaceuticals.

Summary

Corbus Pharmaceuticals beats Enlivex Therapeutics on 8 of the 12 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.